Marc Carrier

List of Publications by Year
in descending order

248 papers	14,827 citations	47006 47 h-index	20961 115 g-index
253 all docs	253 docs citations	253 times ranked	14976 citing authors

#	Article	IF	Citations
1	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. Journal of the American College of Cardiology, 2020, 75, 2950-2973.	2.8	2,392
2	Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. New England Journal of Medicine, 2018, 378, 615-624.	27.0	1,237
3	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 790-802.	27.0	778
4	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 777-789.	27.0	712
5	Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. New England Journal of Medicine, 2019, 380, 711-719.	27.0	614
6	Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019. Chest, 2020, 158, 1143-1163.	0.8	531
7	American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Advances, 2021, 5, 927-974.	5.2	431
8	Systematic Review: Case-Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding Events Among Patients Treated for Venous Thromboembolism. Annals of Internal Medicine, 2010, 152, 578.	3.9	401
9	Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. New England Journal of Medicine, 2018, 378, 699-707.	27.0	294
10	Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. JAMA Internal Medicine, 2019, 179, 1469.	5.1	283
11	Consensus Statements on the Risk, Prevention, and Treatment of Venous Thromboembolism in Inflammatory Bowel Disease: Canadian Association of Gastroenterology. Gastroenterology, 2014, 146, 835-848.e6.	1.3	277
12	Systematic Review: The Trousseau Syndrome Revisited: Should We Screen Extensively for Cancer in Patients with Venous Thromboembolism?. Annals of Internal Medicine, 2008, 149, 323.	3.9	261
13	Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ, The, 2021, 375, n2400.	6.0	250
14	Screening for Occult Cancer in Unprovoked Venous Thromboembolism. New England Journal of Medicine, 2015, 373, 697-704.	27.0	239
15	Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. Thrombosis Research, 2019, 173, 158-163.	1.7	228
16	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thrombosis and Haemostasis, 2020, 120, 1004-1024.	3.4	206
17	Development of a Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism in Patients With Cancer-Associated Venous Thromboembolism. Circulation, 2012, 126, 448-454.	1.6	179
18	Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ: British Medical Journal, 2019, 366, l4363.	2.3	177

#	Article	IF	Citations
19	Guidance for the prevention and treatment of cancer-associated venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2016, 41, 81-91.	2.1	169
20	Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ, The, 2013, 347, f5133-f5133.	6.0	158
21	Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study. Thrombosis and Haemostasis, 2018, 118, 842-851.	3.4	157
22	Efficacy and Safety of Anticoagulant Therapy for the Treatment of Acute Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis. Thrombosis Research, 2014, 134, 1214-1219.	1.7	154
23	Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. Thrombosis and Haemostasis, 2018, 118, 1439-1449.	3.4	154
24	Perioperative Management of Dabigatran. Circulation, 2015, 132, 167-173.	1.6	133
25	Lack of Evidence to Support Thromboprophylaxis in Hospitalized Medical Patients with Cancer. American Journal of Medicine, 2014, 127, 82-86.e1.	1.5	132
26	Clinical and Safety Outcomes Associated With Treatment of Acute Venous Thromboembolism. JAMA - Journal of the American Medical Association, 2014, 312, 1122.	7.4	126
27	Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Thrombosis Research, 2017, 151, 89-95.	1.7	109
28	The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2019, 17, 1772-1778.	3.8	107
29	Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood, 2020, 136, 1433-1441.	1.4	106
30	Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism. Annals of Internal Medicine, 2017, 167, 410.	3.9	96
31	Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. BMJ Open, 2014, 4, e004301-e004301.	1.9	93
32	Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Journal of Thrombosis and Haemostasis, 2020, 18, 2126-2137.	3.8	84
33	Effect of Antiplatelet Therapy on Survival and Organ Supportâ€"Free Days in Critically Ill Patients With COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 1247.	7.4	83
34	Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale. Thrombosis Research, 2015, 136, 727-731.	1.7	78
35	The impact of oral anticoagulation on time to surgery in patients hospitalized with hip fracture. Thrombosis Research, 2015, 136, 962-965.	1.7	77
36	Therapeutic Plasma Exchange in Vaccine-Induced Immune Thrombotic Thrombocytopenia. New England Journal of Medicine, 2021, 385, 857-859.	27.0	70

#	Article	IF	Citations
37	A meta-analysis of low-molecular-weight heparin to prevent pregnancy loss in women with inherited thrombophilia. Blood, 2016, 127, 1650-1655.	1.4	67
38	Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: A systematic review and meta-analysis. Thrombosis Research, 2014, 133, 682-687.	1.7	66
39	The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale. Thrombosis and Haemostasis, 2017, 117, 2415-2424.	3.4	62
40	Anticoagulation of cancer patients with nonâ€valvular atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2019, 17, 1247-1252.	3.8	60
41	Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patients. Thrombosis Research, 2008, 123, 177-183.	1.7	58
42	Thromboprophylaxis in Patients With COVID-19. Chest, 2022, 162, 213-225.	0.8	58
43	Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial. Clinical Trials, 2020, 17, 491-500.	1.6	56
44	Epidemiology, diagnosis, prevention and treatment of catheter-related thrombosis in children and adults. Thrombosis Research, 2017, 157, 64-71.	1.7	53
45	Incidental venous thromboembolism: is anticoagulation indicated?. Hematology American Society of Hematology Education Program, 2017, 2017, 121-127.	2.5	52
46	Development of a Risk Prediction Score for Occult Cancer in Patients With VTE. Chest, 2017, 151, 564-571.	0.8	51
47	Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis. Thrombosis Research, 2014, 134, 93-95.	1.7	50
48	Outcome of central venous catheter associated upper extremity deep vein thrombosis in cancer patients. Thrombosis Research, 2015, 135, 298-302.	1.7	49
49	Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood, 2016, 127, 2035-2037.	1.4	47
50	Management of anticoagulation for cancerâ€associated thrombosis in patients with thrombocytopenia: A systematic review. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 664-669.	2.3	47
51	How I treat cancer-associated venous thromboembolism. Blood, 2019, 133, 291-298.	1.4	45
52	Incidence and risk factors of symptomatic venous thromboembolism related to implanted ports in cancer patients. Thrombosis Research, 2014, 133, 30-33.	1.7	44
53	Comprehensive mitigation framework for concurrent application of multiple clinical practice guidelines. Journal of Biomedical Informatics, 2017, 66, 52-71.	4.3	44
54	Symptomatic subsegmental pulmonary embolism: to treat or not to treat?. Hematology American Society of Hematology Education Program, 2017, 2017, 237-241.	2.5	44

#	Article	IF	Citations
55	Extended treatment with edoxaban in cancer patients with venous thromboembolism: A postâ€hoc analysis of the Hokusaiâ€VTE Cancer study. Journal of Thrombosis and Haemostasis, 2019, 17, 1866-1874.	3.8	42
56	VIDAS D-dimer in combination with clinical pre-test probability to rule out pulmonary embolism. A systematic review of management outcome studies. Thrombosis and Haemostasis, 2009, 101, 886-92.	3.4	42
57	Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2019, 17, 2141-2151.	3.8	41
58	Randomized trials of therapeutic heparin for COVIDâ€19: A metaâ€analysis. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12638.	2.3	39
59	Cancer, atrial fibrillation, and stroke. Thrombosis Research, 2017, 155, 101-105.	1.7	36
60	Predicting the risk of recurrent venous thromboembolism in patients with cancer: A prospective cohort study. Thrombosis Research, 2018, 163, 41-46.	1.7	36
61	Risk of Venous Thromboembolism After Hospital Discharge in Patients With Inflammatory Bowel Disease: A Population-based Study. Inflammatory Bowel Diseases, 2020, 26, 1761-1768.	1.9	35
62	The prevalence of antibodies to the platelet factor 4 -heparin complex and association with access thrombosis in patients on chronic hemodialysis. Thrombosis Research, 2007, 120, 215-220.	1.7	33
63	Risk of Hospitalization With Hemorrhage Among Older Adults Taking Clarithromycin vs Azithromycin and Direct Oral Anticoagulants. JAMA Internal Medicine, 2020, 180, 1052.	5.1	33
64	Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation. Annals of Internal Medicine, 2022, 175, 29-35.	3.9	33
65	Risk of venous thromboembolism in pregnant women with essential thrombocythemia: a systematic review and meta-analysis. Blood, 2017, 129, 934-939.	1.4	32
66	Perioperative interruption of direct oral anticoagulants in patients with atrial fibrillation: A systematic review and metaâ€analysis. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 282-290.	2.3	32
67	Current guidelines do not sufficiently discriminate venous thromboembolism risk in urology. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 457.e1-457.e8.	1.6	31
68	Treatment of Superficial Vein Thrombosis: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis, 2019, 119, 479-489.	3.4	31
69	A clinical predictive model for postâ€hospitalisation venous thromboembolism in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2019, 49, 1493-1501.	3.7	31
70	Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal, 2020, 55, 1901697.	6.7	31
71	A systematic review of clinical practice guidelines on the use of low molecular weight heparin and fondaparinux for the treatment and prevention of venous thromboembolism: Implications for research and policy decision-making. PLoS ONE, 2018, 13, e0207410.	2.5	29
72	Extended treatment of venous thromboembolism: a systematic review and network meta-analysis. Heart, 2019, 105, 545-552.	2.9	29

#	Article	IF	Citations
73	Management of venous thromboembolism in patients with glioma. Thrombosis Research, 2017, 156, 105-108.	1.7	28
74	Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial. Thrombosis Research, 2018, 164, S124-S129.	1.7	28
75	Residual pulmonary embolism as a predictor for recurrence after a first unprovoked episode: Results from the REVERSE cohort study. Thrombosis Research, 2018, 162, 104-109.	1.7	27
76	Extended thromboprophylaxis with low-molecular weight heparin (LMWH) following abdominopelvic cancer surgery. American Journal of Surgery, 2019, 218, 537-550.	1.8	27
77	Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2021, 19, 297-303.	3.8	27
78	Anticoagulant medication adherence for cancerâ€associated thrombosis: A comparison of LMWH to DOACs. Journal of Thrombosis and Haemostasis, 2021, 19, 212-220.	3.8	27
79	VTE Prophylaxis in Critically Ill Adults. Chest, 2022, 161, 418-428.	0.8	27
80	Outcomes in a nurse-led peripherally inserted central catheter program: a retrospective cohort study. CMAJ Open, 2017, 5, E535-E539.	2.4	26
81	The prevention and management of asparaginaseâ€related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH. Journal of Thrombosis and Haemostasis, 2020, 18, 278-284.	3.8	26
82	Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus. Current Oncology, 2021, 28, 5434-5451.	2.2	26
83	Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research, 2017, 151, 67-71.	1.7	25
84	Bleeding risk in patients with unprovoked venous thromboembolism: A critical appraisal of clinical prediction scores. Thrombosis Research, 2017, 152, 52-60.	1.7	25
85	Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study. Thrombosis and Haemostasis, 2022, 122, 646-656.	3.4	25
86	Longâ€term risk of postthrombotic syndrome after symptomatic distal deep vein thrombosis: The CACTUSâ€PTS study. Journal of Thrombosis and Haemostasis, 2020, 18, 857-864.	3.8	24
87	Prophylactic and therapeutic anticoagulation for thrombosisâ€"major issues in oncology. Nature Clinical Practice Oncology, 2009, 6, 74-84.	4.3	23
88	Controversies in the management of cancer-associated thrombosis. Expert Review of Hematology, 2017, 10, 15-22.	2.2	23
89	Ideating Mobile Health Behavioral Support for Compliance to Therapy for Patients with Chronic Disease: A Case Study of Atrial Fibrillation Management. Journal of Medical Systems, 2018, 42, 234.	3.6	23
90	Effect of oral anticoagulant use on surgical delay and mortality in hip fracture. Bone and Joint Journal, 2021, 103-B, 222-233.	4.4	23

#	Article	IF	Citations
91	Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapiesâ€"TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy. Journal of Thrombosis and Haemostasis, 2021, 19, 2068-2081.	3.8	23
92	Efficacy and Safety of Low Molecular Weight Heparin Versus Unfractionated Heparin for Prevention of Venous Thromboembolism in Trauma Patients. Annals of Surgery, 2022, 275, 19-28.	4.2	23
93	Costâ€effectiveness analysis of lowâ€dose direct oral anticoagulant (DOAC) for the prevention of cancerâ€associated thrombosis in the United States. Cancer, 2020, 126, 1736-1748.	4.1	23
94	The use of extended perioperative low molecular weight heparin (tinzaparin) to improve disease-free survival following surgical resection of colon cancer. Blood Coagulation and Fibrinolysis, 2011, 22, 760-762.	1.0	22
95	Periprocedural interruption of anticoagulation in patients with cancerâ€associated venous thromboembolism: An analysis of thrombotic and bleeding outcomes. Journal of Thrombosis and Haemostasis, 2019, 17, 1171-1178.	3.8	22
96	Management of hemostatic complications in acute leukemia: Guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2020, 18, 3174-3183.	3.8	22
97	Thrombotic Complications Associated with Immune Checkpoint Inhibitors. Cancers, 2021, 13, 4606.	3.7	22
98	Outcomes among patients with cancer and incidental or symptomatic venous thromboembolism: A systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2021, 19, 2468-2479.	3.8	21
99	Effect of occult cancer screening on mortality in patients with unprovoked venous thromboembolism. Thrombosis Research, 2018, 171, 92-96.	1.7	20
100	Diagnostic accuracy of three ultrasonography strategies for deep vein thrombosis of the lower extremity: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0228788.	2.5	20
101	Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis. Haematologica, 2020, 105, 1436-1442.	3.5	19
102	Hyperacute multi-organ thromboembolic storm in COVID-19: a case report. Journal of Thrombosis and Thrombolysis, 2021, 51, 25-28.	2.1	19
103	Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID) Tj ETQq1 1 0.784314 rgBT /Overl Trials, 2021, 22, 202.	1.6	19
104	Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study. Blood Advances, 2022, 6, 3569-3578.	5.2	19
105	Excluding pulmonary embolism at the bedside with low pre-test probability and D-dimer: Safety and clinical utility of 4 methods to assign pre-test probability. Thrombosis Research, 2006, 117, 469-474.	1.7	18
106	The use of anticoagulants for the treatment and prevention of venous thromboembolism in obese patients: implications for safety. Expert Opinion on Drug Safety, 2016, 15, 65-74.	2.4	18
107	Management of Cancer-Associated Thrombosis: Unmet Needs and Future Perspectives. TH Open, 2021, 05, e376-e386.	1.4	18
108	Treatment of cancer-associated thrombosis: perspectives on the use of novel oral anticoagulants. Thrombosis Research, 2014, 133, S167-S171.	1.7	17

#	Article	IF	Citations
109	Using Semantic Components to Represent Dynamics of an Interdisciplinary Healthcare Team in a Multi-Agent Decision Support System. Journal of Medical Systems, 2016, 40, 42.	3.6	17
110	How I treat obese patients with oral anticoagulants. Blood, 2020, 135, 904-911.	1.4	17
111	The efficacy and safety of anticoagulation in cerebral vein thrombosis: A systematic review and meta-analysis. Thrombosis Research, 2018, 169, 135-139.	1.7	16
112	Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. Journal of Thrombosis and Thrombolysis, 2019, 47, 495-504.	2.1	16
113	Prevention of venous thromboembolism in ambulatory patients with cancer. ESMO Open, 2020, 5, e000948.	4.5	16
114	Risk Scores for Occult Cancer in Patients with Venous Thromboembolism: A Post Hoc Analysis of the Hokusai-VTE Study. Thrombosis and Haemostasis, 2018, 118, 1270-1278.	3.4	15
115	The Efficacy and Safety of Low Molecular Weight Heparin Administration to Improve Survival of Cancer Patients: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis, 2020, 120, 832-846.	3.4	15
116	Extended thromboprophylaxis following major abdominal/pelvic cancer-related surgery: A systematic review and meta-analysis of the literature. Thrombosis Research, 2021, 204, 114-122.	1.7	15
117	Venous thromboembolism and occult cancer: impact on clinical practice. Thrombosis Research, 2016, 140, S8-S11.	1.7	14
118	Screening for cancer in patients with unprovoked venous thromboembolism: protocol for a systematic review and individual patient data meta-analysis. BMJ Open, 2017, 7, e015562.	1.9	14
119	Discordant reporting of VTE in pancreatic cancer: A systematic review and metaâ€analysis of thromboprophylaxis versus chemotherapeutic trials. Journal of Thrombosis and Haemostasis, 2021, 19, 489-501.	3.8	14
120	Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELDâ€VTE. Journal of Thrombosis and Haemostasis, 2021, 19, 3031-3043.	3.8	14
121	Risk of major bleeding in patients receiving vitamin K antagonists or low doses of aspirin. A systematic review and meta-analysis. Thrombosis Research, 2016, 138, 1-6.	1.7	13
122	Management of suspected and confirmed recurrent venous thrombosis while on anticoagulant therapy. What next?. Thrombosis Research, 2019, 180, 105-109.	1.7	13
123	Clinical Surveillance vs. Anticoagulation For low-risk patiEnts with isolated SubSegmental Pulmonary Embolism: protocol for a multicentre randomised placebo-controlled non-inferiority trial (SAFE-SSPE). BMJ Open, 2020, 10, e040151.	1.9	13
124	Longâ€term risk of recurrent venous thromboembolism after a first contraceptiveâ€related event: Data from REVERSE cohort study. Journal of Thrombosis and Haemostasis, 2021, 19, 1526-1532.	3.8	12
125	Recurrent bleeding and thrombotic events after resumption of oral anticoagulants following gastrointestinal bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation. Journal of Thrombosis and Haemostasis, 2021, 19, 2618-2628.	3.8	12
126	Thromboembolic disease in palliative and end-of-life care: A narrative review. Thrombosis Research, 2019, 175, 84-89.	1.7	11

#	Article	IF	Citations
127	Anticoagulation for Subsegmental Pulmonary Embolism. New England Journal of Medicine, 2019, 381, 1171-1174.	27.0	11
128	Ventilation/perfusion SPECT for the diagnosis of pulmonary embolism: A systematic review. Journal of Thrombosis and Haemostasis, 2020, 18, 2910-2920.	3.8	11
129	Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial. Thrombosis Research, 2021, 202, 151-154.	1.7	11
130	SPECT V/Q for the diagnosis of pulmonary embolism: protocol for a systematic review and meta-analysis of diagnostic accuracy and clinical outcome. BMJ Open, 2018, 8, e022024.	1.9	10
131	Venous thromboembolism and transfusion after major abdominopelvic surgery. Surgery, 2019, 166, 1084-1091.	1.9	10
132	Risk scores for occult cancer in patients with unprovoked venous thromboembolism: Results from an individual patient data metaâ€analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 2622-2628.	3.8	10
133	Screening for Occult Cancer in Patients with Venous Thromboembolism. Journal of Clinical Medicine, 2020, 9, 2389.	2.4	10
134	Biomarkers in cancer patients at risk for venous thromboembolism: data from the AVERT study. Thrombosis Research, 2020, 191, S31-S36.	1.7	10
135	Effect of oral anticoagulants on hemostatic and thromboembolic complications in hip fracture: A systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 2566-2581.	3.8	10
136	MitPlan: A planning approach to mitigating concurrently applied clinical practice guidelines. Artificial Intelligence in Medicine, 2021, 112, 102002.	6.5	10
137	Oral Anticoagulant Use in Patients with Morbid Obesity: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis, 2022, 122, 830-841.	3.4	10
138	Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. Journal of Thrombosis and Haemostasis, 2021, 19, 3008-3017.	3.8	10
139	Efficacy and safety of apixaban for primary prevention of thromboembolism in patients with cancer and a central venous catheter: A subgroup analysis of the AVERT Trial. Thrombosis Research, 2022, 216, 8-10.	1.7	10
140	Management of pregnancy associated venous-thromboembolism: a survey of practices. Thrombosis Journal, 2014, 12, 12.	2.1	9
141	Revisiting occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research, 2018, 164, S7-S11.	1.7	9
142	Safety of Primary Thromboprophylaxis Using Apixaban in Ambulatory Cancer Patients with Intracranial Metastatic Disease or Primary Brain Tumors. Thrombosis and Haemostasis, 2019, 119, 1886-1887.	3.4	9
143	D-Dimer Enhances Risk-Targeted Thromboprophylaxis in Ambulatory Patients with Cancer. Oncologist, 2020, 25, 1075-1083.	3.7	9
144	Surgery and the Subtype of Inflammatory Bowel Disease Impact the Risk of Venous Thromboembolism After Hospital Discharge. Digestive Diseases and Sciences, 2022, 67, 2471-2479.	2.3	9

#	Article	IF	Citations
145	Incidence and Risk Factors of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Agents. Blood, 2016, 128, 2624-2624.	1.4	9
146	Costâ€"utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer. Cmaj, 2021, 193, E1551-E1560.	2.0	9
147	Should we screen patients with unprovoked venous thromboembolism for occult cancers? A pilot study. Blood Coagulation and Fibrinolysis, 2010, 21, 709-710.	1.0	8
148	Occult cancer detection in venous thromboembolism: the past, the present, and the future. Research and Practice in Thrombosis and Haemostasis, 2017, 1, 9-13.	2.3	8
149	A new prognostic strategy for adult patients with acute pulmonary embolism eligible for outpatient therapy. Journal of Thrombosis and Thrombolysis, 2017, 43, 326-332.	2.1	8
150	Patient-Centered Outcomes in the Management of Anemia: A Scoping Review. Transfusion Medicine Reviews, 2019, 33, 7-11.	2.0	8
151	Implanted vascular access device related deep vein thrombosis in oncology patients: A prospective cohort study. Thrombosis Research, 2019, 177, 117-121.	1.7	8
152	Patient-Centred Outcomes in Anaemia and Renal Disease: A Systematic Review. Kidney Diseases (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10	2.5	8
153	A systematic review on the efficacy and safety of low molecular weight heparin as an anticancer therapeutic in preclinical animal models. Thrombosis Research, 2020, 195, 103-113.	1.7	8
154	A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome. Pilot and Feasibility Studies, 2020, 6, 52.	1.2	8
155	Venous thromboembolic events in inflammatory bowel diseases: A review of current evidence and guidance on risk in the post-hospitalization setting. Thrombosis Research, 2020, 194, 26-32.	1.7	8
156	Activated prothrombin complex concentrates for direct oral anticoagulant-associated bleeding or urgent surgery: Hemostatic and thrombotic outcomes. Thrombosis Research, 2020, 195, 21-28.	1.7	8
157	Safety and efficacy of apixaban thromboprophylaxis in cancer patients with metastatic disease: A post-hoc analysis of the AVERT trial. Thrombosis Research, 2021, 197, 13-15.	1.7	8
158	Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIMâ€Line): A twoâ€center openâ€label pilot randomized controlled trial. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12517.	2.3	8
159	Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantation. American Journal of Hematology, 2021, 96, 1137-1146.	4.1	8
160	Heparin â€" Messias or Verschlimmbesserung?. Journal of Thrombosis and Haemostasis, 2021, 19, 2373-2382.	3.8	8
161	Timing of Perioperative Pharmacologic Thromboprophylaxis Initiation and its Effect on Venous Thromboembolism and Bleeding Outcomes: A Systematic Review and Meta-Analysis. Journal of the American College of Surgeons, 2021, 233, 619-631.	0.5	8
162	Rivaroxaban Compared to Placebo for the Treatment of Leg Superficial Vein Thrombosis: A Randomized Trial. Seminars in Thrombosis and Hemostasis, 2020, 46, 977-985.	2.7	8

#	Article	IF	Citations
163	Growth differentiation factorâ€15 for prediction of bleeding in cancer patients. Journal of Thrombosis and Haemostasis, 2021, 20, 138.	3.8	8
164	Amiodarone, Verapamil, or Diltiazem Use With Direct Oral Anticoagulants and the Risk of Hemorrhage in Older Adults. CJC Open, 2022, 4, 315-323.	1.5	8
165	POINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? Yes. Chest, 2022, 161, 1446-1448.	0.8	8
166	Patterns of venous thromboembolism risk, treatment, and outcomes among patients with cancer from uninsured and vulnerable populations. American Journal of Hematology, 2022, 97, 1044-1054.	4.1	8
167	Thromboprophylaxis in Cancer Patients. Seminars in Thrombosis and Hemostasis, 2014, 40, 395-400.	2.7	7
168	Determining the safety of enoxaparin prophylaxis in critically ill patients with severe renal insufficiency â€“ The PACER pilot study. Thrombosis Research, 2016, 144, 69-71.	1.7	7
169	Treatment of Venous Thromboembolism in Cancer. Historical Perspective and Evolving Role of the Direct Oral Anticoagulants. Cancer Treatment and Research, 2019, 179, 103-115.	0.5	7
170	An ontology-driven framework to support the dynamic formation of an interdisciplinary healthcare team. International Journal of Medical Informatics, 2020, 136, 104075.	3.3	7
171	Treatment of portal vein thrombosis: an updated narrative review. Minerva Medica, 2022, 112, .	0.9	7
172	Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism. Blood Advances, 2022, 6, 4605-4616.	5.2	7
173	Should we screen extensively for cancer after unprovoked venous thrombosis?. BMJ: British Medical Journal, 2017, 356, j1081.	2.3	6
174	A survey of thrombosis experts evaluating practices and opinions regarding venous thromboprophylaxis in patients post major abdominal surgery. Thrombosis Journal, 2017, 15, 2.	2.1	6
175	Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis. BMJ Open, 2017, 7, 016950.	1.9	6
176	Management of direct oral anticoagulant associated bleeding: Results of a multinational survey. Thrombosis Research, 2018, 163, 19-21.	1.7	6
177	Perioperative interruption of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: A comparative analysis. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 131-140.	2.3	6
178	From cellular function to global impact: the vascular perspective on COVID-19. Canadian Journal of Surgery, 2021, 64, E289-E297.	1.2	6
179	A Health eLearning Ontology and Procedural Reasoning Approach for Developing Personalized Courses to Teach Patients about Their Medical Condition and Treatment. International Journal of Environmental Research and Public Health, 2021, 18, 7355.	2.6	6
180	Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study: A Perioperative Management Plan for Patients with Atrial Fibrillation Who Are Receiving a Direct Oral Anticoagulant. Blood, 2018, 132, LBA-5-LBA-5.	1.4	6

#	Article	IF	Citations
181	A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai VTE-Cancer Study. Blood, 2017, 130, LBA-6-LBA-6.	1.4	6
182	Cancer Screening After Unprovoked Venous Thromboembolism. JAMA Internal Medicine, 2016, 176, 739.	5.1	5
183	Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism. Expert Opinion on Drug Safety, 2019, 18, 313-320.	2.4	5
184	Challenging anticoagulation cases: A case of pulmonary embolism shortly after spontaneous brain bleeding. Thrombosis Research, 2021, 200, 41-47.	1.7	5
185	Efficacy and safety of primary thromboprophylaxis for the prevention of venous thromboembolism in patients with cancer and a central venous catheter: A systematic review and meta-analysis. Thrombosis Research, 2021, 208, 58-65.	1.7	5
186	How to manage patients with symptomatic subsegmental pulmonary embolism?. Polish Archives of Internal Medicine, 2020, 130, 310-316.	0.4	5
187	Residual pulmonary vascular obstruction and recurrence after acute pulmonary embolism: protocol for a systematic review and meta-analysis of individual participant data. BMJ Open, 2018, 8, e023939.	1.9	4
188	What's new in the prevention and treatment of cancer-associated thrombosis?. Hematology American Society of Hematology Education Program, 2019, 2019, 158-166.	2.5	4
189	Direct oral anticoagulants and cancer-associated VTE: good for all, or just some?. Blood, 2020, 136, 669-673.	1.4	4
190	Thromboprophylaxis for patients with newly diagnosed vs. recurrent cancers: a post-hoc analysis of the avert trial. Journal of Thrombosis and Thrombolysis, 2021, 51, 720-724.	2.1	4
191	Meta-Analysis of Long-Term Risk of Recurrent Venous Thromboembolism after Stopping Anticoagulation in Men and Women with First Unprovoked Venous Thromboembolism. Blood, 2018, 132, 2527-2527.	1.4	4
192	A Prospective Cohort Study of Upper Extremity Deep Vein Thrombosis. Blood, 2015, 126, 893-893.	1.4	4
193	Efficacy of primary prevention of venous thromboembolism among subgroups of cancer patients undergoing chemotherapy: A post- hoc analysis of the AVERT trial. Thrombosis Research, 2021, 208, 79-82.	1.7	4
194	Growth Differentiation Factor-15, High-Sensitivity Cardiac Troponin T, and N-Terminal pro-B-type Natriuretic Peptide for Predicting Risk of Venous Thromboembolism in Ambulatory Cancer Patients Receiving Chemotherapy. Thrombosis and Haemostasis, 2022, 122, 1169-1176.	3.4	4
195	Venous thromboembolism risk in patients receiving neoadjuvant chemotherapy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 381.e1-381.e7.	1.6	4
196	Hemorrhage Risk Among Patients With Breast Cancer Receiving Concurrent Direct Oral Anticoagulants With Tamoxifen vs Aromatase Inhibitors. JAMA Network Open, 2022, 5, e2219128.	5.9	4
197	Should we regionalize the management of pulmonary embolism?. Cmaj, 2008, 178, 58-60.	2.0	3
198	Defining time in therapeutic range for busy clinicians: Frequency of dose changes is a good surrogate marker to identify patients with suboptimal anticoagulation with warfarin. Thrombosis Research, 2014, 134, 584-586.	1.7	3

#	Article	IF	Citations
199	The importance of post thrombotic syndrome as an outcome after deep venous thrombosis: A survey of Canadian thrombosis clinicians. Thrombosis Research, 2017, 159, 13-15.	1.7	3
200	Occult cancer detection in patients with hemostatic disorder and venous thromboembolism. Thrombosis Research, 2018, 163, 242-245.	1.7	3
201	Debate: Thromboprophylaxis should be considered in all patients with cancer â€“ Yes. Thrombosis Research, 2020, 191, 142-144.	1.7	3
202	Safety of using direct oral anticoagulants in the diagnostic workup of outpatients with suspicion of acute venous thromboembolism. Haematologica, 2020, 105, e307-e309.	3.5	3
203	Clinical and sociodemographic factors associated with anticoagulant use for cancer associated venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2021, 52, 214-223.	2.1	3
204	Thromboprophylaxis practice patterns and beliefs among physicians treating patients with abdominopelvic cancers at a Canadian centre. Canadian Journal of Surgery, 2020, 63, E562-E568.	1.2	3
205	Prognostic Factors Associated With Development of Venous Thromboembolism in Critically Ill Patientsâ€"A Systematic Review and Meta-Analysis. Critical Care Medicine, 2022, 50, e370-e381.	0.9	3
206	Long-term risk of major bleeding after discontinuing anticoagulation for unprovoked venous thromboembolism: a systematic review and meta-analysis. Thrombosis and Haemostasis, 2021, 0, .	3.4	3
207	Safety and efficacy of apixaban thromboprophylaxis in ambulatory cancer patients according to renal function: A subgroup analysis of the AVERT trial. Thrombosis Research, 2022, 211, 85-87.	1.7	3
208	Standardization of risk prediction model reporting in cancerâ€associated thrombosis: Communication from the ISTHÂSSC subcommittee on hemostasis and malignancy. Journal of Thrombosis and Haemostasis, 2022, 20, 1920-1927.	3.8	3
209	Catheter-related thrombosis: Unresolved issues. Thrombosis Research, 2015, 136, 1055-1056.	1.7	2
210	A survey of thrombosis experts evaluating practices and opinions regarding venous thromboprophylaxis in patients with active cancer hospitalized with an acute medical illness. Thrombosis Journal, 2015, 13, 10.	2.1	2
211	Guiding curriculum development of a national research training program in thrombosis medicine: A needs assessment involving faculty and trainees. Thrombosis Research, 2018, 162, 79-86.	1.7	2
212	Illustrated Stateâ€ofâ€theâ€Art Capsules of the ISTH 2021 Congress. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12532.	2.3	2
213	The Risk of Venous Thromboembolism in Pregnant Women with Essential Thrombocythemia: A Systematic Review and Meta-Analysis. Blood, 2016, 128, 2595-2595.	1.4	2
214	Factors Associated With Inferior Vena Cava Filter Placement and Retrieval for Patients With Cancer-Associated Thrombosis. American Journal of Medicine, 2022, 135, 478-487.e5.	1.5	2
215	Anticoagulation in thrombocytopenic patients â€“ time to rethink?. Journal of Thrombosis and Haemostasis, 0, , .	3.8	2
216	The efficacy and safety of anticoagulation in cerebral vein thrombosis: A Systematic review and meta-analysis. Thrombosis Research, 2019, 180, 28.	1.7	1

#	Article	IF	Citations
217	Just the facts: Management of life-threatening bleeding with oral anticoagulant use in the emergency department. Canadian Journal of Emergency Medicine, 2019, 21, 460-463.	1.1	1
218	Subsegmental pulmonary embolism: May not be a killer but indicates significant risk. Thrombosis Research, 2020, 185, 180-182.	1.7	1
219	Antibodies to the Platelet Factor 4-Heparin Complex and Mortality in Chronic Hemodialysis Patients.. Blood, 2006, 108, 274-274.	1.4	1
220	Treatment of Portal, Mesenteric, and Splenic Vein Thrombosis with Rivaroxaban: A Pilot, Prospective Cohort Study. Blood, 2021, 138, 671-671.	1.4	1
221	Persistence of Platelets Activation Prior to Second Doses of Covid-19 Vaccine After Vaccine-Induced Immune Thrombotic Thrombocytopenia. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962210862.	1.7	1
222	Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation. Annals of Internal Medicine, 2022, 175, W43-W44.	3.9	1
223	The Reply. American Journal of Medicine, 2014, 127, e35.	1.5	0
224	Unusual venous thrombosis. Cmaj, 2014, 186, 697.3-698.	2.0	0
225	The Reply. American Journal of Medicine, 2014, 127, e13.	1.5	0
226	A Survey of the Use of Empiric Novel Anticoagulants During Investigation of Stroke. Canadian Journal of Neurological Sciences, 2015, 42, 135-137.	0.5	0
227	Screening for cancer in unprovoked venous thromboembolism. HemaSphere, 2019, 3, 22-23.	2.7	0
228	Predictors of long-term cancer diagnosis after an unprovoked thromboembolic event: A post-hoc analysis of the REVERSE cohort study. Thrombosis Research, 2020, 185, 132-134.	1.7	0
229	Biomarker-enhanced VTE risk stratification in ambulatory patients with cancer. Thrombosis Research, 2020, 196, 437-443.	1.7	0
230	Antithrombotic regimens in females with symptomatic lower extremity peripheral arterial disease: protocol for a systematic review and meta-analysis. BMJ Open, 2021, 11, e042980.	1.9	0
231	Media portrayals of pulmonary embolism. Thrombosis Research, 2021, 206, 52-54.	1.7	0
232	High Prevalence of Antibodies to the Heparin-Platelet Factor 4 Complex in Hemodialysis Patients.. Blood, 2005, 106, 4119-4119.	1.4	0
233	Practical Application of the 10 Mg Warfarin Initiation Nomogram. Blood, 2008, 112, 4054-4054.	1.4	0
234	Perioperative Management Of Patients On Dabigatran â€“ a Prospective Cohort Study. Blood, 2013, 122, 3637-3637.	1.4	0

#	Article	IF	Citations
235	Risk of Venous Thromboembolism in Hospitalized Patients with Sickle Cell Disease. Blood, 2016, 128, 4755-4755.	1.4	0
236	Thrombotic and Bleeding Outcomes Following Perioperative Interruption of Direct Oral Anticoagulants and Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation - a Comparative Analysis. Blood, 2018, 132, 1234-1234.	1.4	0
237	Long-Term Risk Factors for Occult Cancer Detection in Patients with Unprovoked Venous Thromboembolism: A Post-Hoc Analysis of the Reverse Study. Blood, 2018, 132, 1230-1230.	1.4	0
238	Cost-Utility Analysis of Apixaban Compared to Usual Care for the Primary Thromboprophylaxis of Ambulatory Cancer Patients Initiating Chemotherapy. Blood, 2019, 134, 329-329.	1.4	0
239	Meta-Analysis and Cost-Effectiveness Analysis of Low-Dose Direct Oral Anticoagulant for the Prevention of Cancer Associated Thrombosis. Blood, 2019, 134, 4669-4669.	1.4	0
240	Expanding a First-Order Logic Mitigation Framework to Handle Multimorbid Patient Preferences. AMIA ... Annual Symposium proceedings, 2015, 2015, 895-904.	0.2	0
241	Efficacy and Safety of Primary Thromboprophylaxis for the Prevention of Venous Thromboembolism in Patients with Cancer and Central Venous Catheter: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 2139-2139.	1.4	0
242	A Population Cohort Study to Evaluate the Risk of Ischemic Stroke Among Individuals with a New Diagnosis of Cancer Compared to Matched Cancer-Free Controls: Impact of Prior Stroke History. Blood, 2021, 138, 175-175.	1.4	0
243	Efficacy and Safety of Apixaban for Primary Prevention of Thromboembolism in Cancer Patients with a Newly Inserted Central Venous Catheter: A Post-Hoc Analysis of the Avert Trial. Blood, 2021, 138, 2133-2133.	1.4	0
244	Impact of Race/Ethnicity on Cancer Associated Thrombosis Among Underserved Patients with Cancer. Blood, 2021, 138, 176-176.	1.4	0
245	A Framework for Modeling Workflow Execution by an Interdisciplinary Healthcare Team. Studies in Health Technology and Informatics, 2015, 216, 1100.	0.3	0
246	Rebuttal From Dr Tritschler etÂal. Chest, 2022, , .	0.8	0
247	Towards a framework for comparing functionalities of multimorbidity clinical decision support: A literature-based feature set and benchmark cases.. AMIA ... Annual Symposium proceedings, 2021, 2021, 920-929.	0.2	0
248	Step down to six months of prophylacticâ€dose lowâ€molecularâ€weight heparin after initial fullâ€dose anticoagulation for the treatment of cancerâ€associated thrombosis (<scp>STEPâ€CAT</scp>): a pilot study. Journal of Thrombosis and Haemostasis, 2022, , .	3.8	0